Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2017 (2017), Article ID 5620314, 13 pages
https://doi.org/10.1155/2017/5620314
Review Article

The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy

Division of Cardiology, Department of Cardio-Thoracic and Respiratory Sciences, University of Campania “Luigi Vanvitelli” and A.O. dei Colli Monaldi Hospital, Naples, Italy

Correspondence should be addressed to Paolo Calabrò

Received 13 January 2017; Revised 15 March 2017; Accepted 23 March 2017; Published 28 May 2017

Academic Editor: Shengbo Cao

Copyright © 2017 Felice Gragnano et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. A. Willebrand, “Hereditar pseudohemofili,” Finska Lakarsallskapets Hand, vol. 1, no. 67, pp. 7–112, 1926. View at Google Scholar
  2. I. M. Nilsson, “In memory of Erik Jorpes. von Willebrand’s disease from 1926-1983,” Scandinavian Journal of Haematology. Supplementum, vol. 40, no. 33, pp. 21–43, 1984. View at Google Scholar
  3. D. Meyer and M. J. Larrieu, “Von Willebrand factor and platelet adhesiveness,” Journal of Clinical Pathology, vol. 23, no. 3, pp. 228–231, 1970. View at Publisher · View at Google Scholar
  4. T. S. Zimmerman, O. D. Ratnoff, and A. E. Powell, “Immunologic differentiation of classic hemophilia (factor VIII deficiency) and von Willebrand’s disease, with observations on combined deficiencies of antihemophilic factor and proaccelerin (factor V) and on an acquired circulating anticoagulant against antihemophilic factor,” The Journal of Clinical Investigation, vol. 50, no. 1, pp. 244–254, 1971. View at Publisher · View at Google Scholar
  5. P. J. Lenting, C. Casari, O. D. Christophe, and C. V. Denis, “von Willebrand factor: the old, the new and the unknown,” Journal of Thrombosis and Haemostasis, vol. 10, no. 12, pp. 2428–2437, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. Y. F. Zhou, E. T. Eng, J. Zhu, C. Lu, T. Walz, and T. A. Springer, “Sequence and structure relationships within von Willebrand factor,” Blood, vol. 120, no. 2, pp. 449–458, 2012. View at Google Scholar
  7. M. Bryckaert, J. P. Rosa, C. V. Denis, and P. J. Lenting, “Of von Willebrand factor and platelets,” Cellular and Molecular Life Sciences, vol. 72, no. 2, pp. 307–326, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. T. A. Springer, “von Willebrand factor, Jedi knight of the bloodstream,” Blood, vol. 124, no. 9, pp. 1412–1425, 2014. View at Publisher · View at Google Scholar
  9. A. Padilla, J. L. Moake, A. Bernardo et al., “P-selectin anchors newly released ultralarge von Willebrand factor multimers to the endothelial cell surface,” Blood, vol. 103, no. 6, pp. 2150–6, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. J. T. Crawley, R. de Groot, Y. Xiang, B. M. Luken, and D. A. Lane, “Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor,” Blood, vol. 118, no. 12, pp. 3212–3221, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Sorrentino, J. D. Studt, O. Medalia, and K. Tanuj Sapra, “Roll, adhere, spread and contract: structural mechanics of platelet function,” European Journal of Cell Biology, vol. 94, no. 3-4, pp. 129–138, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. S. P. Jackson, “The growing complexity of platelet aggregation,” Blood, vol. 109, no. 12, pp. 5087–5095, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. Z. M. Ruggeri, “Structure of von Willebrand factor and its function in platelet adhesion and thrombus formation,” Best Practice & Research. Clinical Haematology, vol. 14, no. 2, pp. 257–279, 2001. View at Google Scholar
  14. N. L. Smith, M. H. Chen, A. Dehghan et al., “Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium,” Circulation, vol. 121, no. 12, pp. 1382–1392, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. U. M. Vischer, “von Willebrand factor, endothelial dysfunction, and cardiovascular disease,” Journal of Thrombosis and Haemostasis, vol. 4, no. 6, pp. 1186–1193, 2006. View at Publisher · View at Google Scholar
  16. U. M. Vischer, F. R. Herrmann, T. Peyrard, R. Nzietchueng, and A. Benetos, “Plasma von Willebrand factor and arterial aging,” Journal of Thrombosis and Haemostasis, vol. 3, no. 4, pp. 794-795, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. J. A. van Mourik, R. Boertjes, I. A. Huisveld et al., “von Willebrand factor propeptide in vascular disorders: a tool to distinguish between acute and chronic endothelial cell perturbation,” Blood, vol. 94, no. 1, pp. 179–185, 1999. View at Publisher · View at Google Scholar
  18. D. A. Brott, A. Katein, H. Thomas et al., “Evaluation of von Willebrand factor and von Willebrand factor propeptide in models of vascular endothelial cell activation, perturbation, and/or injury,” Toxicologic Pathology, vol. 42, no. 4, pp. 672–683, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Zarei, M. Frieden, J. E. Kaufmann, and U. M. Vischer, “The regulation of endothelial VWF secretion by nitric oxide: is it physiological?” Journal of Thrombosis and Haemostasis, vol. 4, no. 1, pp. 263–265, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Schwameis, C. Schörgenhofer, A. Assinger, M. M. Steiner, and B. Jilma, “VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP,” Thrombosis and Haemostasis, vol. 113, no. 4, pp. 708–718, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. S. F. De Meyer, F. Denorme, F. Langhauser, E. Geuss, F. Fluri, and C. Kleinschnitz, “Thromboinflammation in stroke brain damage,” Stroke, vol. 47, no. 4, pp. 1165–1172, 2016. View at Publisher · View at Google Scholar · View at Scopus
  22. B. Engelmann and S. Massberg, “Thrombosis as an intravascular effector of innate immunity,” Nature Reviews. Immunology, vol. 13, no. 1, pp. 34–45, 2013. View at Google Scholar
  23. R. Pendu, V. Terraube, O. D. Christophe et al., “P-selectin glycoprotein ligand 1 and beta2-integrins cooperate in the adhesion of leukocytes to von Willebrand factor,” Blood, vol. 108, no. 12, pp. 3746–3752, 2006. View at Google Scholar
  24. E. Golia, G. Limongelli, F. Natale et al., “Adipose tissue and vascular inflammation in coronary artery disease,” World Journal of Cardiology, vol. 6, no. 7, pp. 539–554, 2014. View at Publisher · View at Google Scholar
  25. L. Forte, G. Cimmino, F. Loffredo et al., “C-reactive protein is released in the coronary circulation and causes endothelial dysfunction in patients with acute coronary syndromes,” International Journal of Cardiology, vol. 152, no. 1, pp. 7–12, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. P. Calabrò, E. Golia, and E. T. Yeh, “Role of C-reactive protein in acute myocardial infarction and stroke: possible therapeutic approaches,” Current Pharmaceutical Biotechnology, vol. 13, no. 1, pp. 4–16, 2012. View at Google Scholar
  27. B. Memoli, A. Procino, P. Calabrò et al., “Inflammation may modulate IL-6 and C-reactive protein gene expression in the adipose tissue: the role of IL-6 cell membrane receptor,” American Journal of Physiology. Endocrinology and Metabolism, vol. 293, no. 4, pp. E1030–E1035, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. B. E. Pottinger, R. C. Read, E. M. Paleolog, P. G. Higgins, and J. D. Pearson, “von Willebrand factor is an acute phase reactant in man,” Thrombosis Research, vol. 53, no. 4, pp. 387–394, 1989. View at Google Scholar
  29. J. B. Meigs, M. A. Mittleman, D. M. Nathan et al., “Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study,” Jama, vol. 283, no. 2, pp. 221–228, 2000. View at Publisher · View at Google Scholar
  30. A. Jager, V. W. van Hinsbergh, P. J. Kostense et al., “von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 12, pp. 3071–3078, 1999. View at Publisher · View at Google Scholar
  31. C. L. Bockmeyer, R. A. Claus, U. Budde et al., “Inflammation-associated ADAMTS13 deficiency promotes formation of ultra-large von Willebrand factor,” Haematologica, vol. 93, no. 1, pp. 137–140, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. U. M. Vischer, H. Barth, and C. B. Wollheim, “Regulated von Willebrand factor secretion is associated with agonist-specific patterns of cytoskeletal remodeling in cultured endothelial cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 3, pp. 883–891, 2000. View at Google Scholar
  33. A. Bernardo, C. Ball, L. Nolasco, J. F. Moake, and J. F. Dong, “Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow,” Blood, vol. 104, no. 1, pp. 100–106, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. K. Ley, “Molecular mechanisms of leukocyte recruitment in the inflammatory process,” Cardiovascular Research, vol. 32, no. 4, pp. 733–742, 1996. View at Google Scholar
  35. R. P. McEver and R. D. Cummings, “Perspectives series: cell adhesion in vascular biology: role of PSGL-1 binding to selectins in leukocyte recruitment,” The Journal of Clinical Investigation, vol. 100, no. 3, pp. 485–491, 1997. View at Publisher · View at Google Scholar
  36. C. Cerletti, V. Evangelista, and G. de Gaetano, “P-selectin-beta 2-integrin cross-talk: a molecular mechanism for polymorphonuclear leukocyte recruitment at the site of vascular damage,” Thrombosis and Haemostasis, vol. 82, no. 2, pp. 787–793, 1999. View at Google Scholar
  37. D. D. Wagner, “The Weibel-Palade body: the storage granule for von Willebrand factor and P-selectin,” Thrombosis and Haemostasis, vol. 70, no. 1, pp. 105–110, 1993. View at Google Scholar
  38. C. V. Denis, P. André, S. Saffaripour, and D. D. Wagner, “Defect in regulated secretion of P-selectin affects leukocyte recruitment in von Willebrand factor-deficient mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 7, pp. 4072–4077, 2001. View at Publisher · View at Google Scholar · View at Scopus
  39. E. Koivunen, T. M. Ranta, A. Annila et al., “Inhibition of β2integrin–mediated leukocyte cell adhesion by leucine–leucine–glycine motif–containing peptides,” The Journal of Cell Biology, vol. 153, no. 5, pp. 905–916, 2001. View at Google Scholar
  40. A. Bernardo, C. Ball, L. Nolasco, H. Choi, J. L. Moake, and J. F. Dong, “Platelets adhered to endothelial cell-bound ultra-large von Willebrand factor strings support leukocyte tethering and rolling under high shear stress,” Journal of Thrombosis and Haemostasis, vol. 3, no. 3, pp. 562–570, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. B. Petri, A. Broermann, H. Li et al., “von Willebrand factor promotes leukocyte extravasation,” Blood, vol. 116, no. 22, pp. 4712–4719, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. J. M. Thurman and V. M. Holers, “The central role of the alternative complement pathway in human disease,” Journal of Immunology, vol. 176, no. 3, pp. 1305–1310, 2006. View at Google Scholar
  43. N. A. Turner and J. Moake, “Assembly and activation of alternative complement components on endothelial cell-anchored ultra-large von Willebrand factor links complement and hemostasis-thrombosis,” PloS One, vol. 8, no. 3, article e59372, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. N. Turner, L. Nolasco, J. Nolasco, S. Sartain, and J. Moake, “Thrombotic microangiopathies and the linkage between von Willebrand factor and the alternative complement pathway,” Seminars in Thrombosis and Hemostasis, vol. 40, no. 5, pp. 544–550, 2014. View at Publisher · View at Google Scholar · View at Scopus
  45. C. M. Cserti, S. Landaw, and L. Uhl, “Do infections provoke exacerbations and relapses of thrombotic thrombocytopenic purpura?” Journal of Clinical Apheresis, vol. 22, no. 1, pp. 21–25, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. M. Réti, P. Farkas, D. Csuka et al., “Complement activation in thrombotic thrombocytopenic purpura,” Journal of Thrombosis and Haemostasis, vol. 10, no. 5, pp. 791–798, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. K. Kambas, I. Mitroulis, and K. Ritis, “The emerging role of neutrophils in thrombosis—the journey of TF through NETs,” Frontiers in Immunology, vol. 3, p. 385, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. K. Quinn, M. Henriques, T. Parker, A. S. Slutsky, and H. Zhang, “Human neutrophil peptides: a novel potential mediator of inflammatory cardiovascular diseases,” American Journal of Physiology. Heart and Circulatory Physiology, vol. 295, no. 5, pp. H1817–H1824, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. V. G. Pillai, J. Bao, C. B. Zander et al., “Human neutrophil peptides inhibit cleavage of von Willebrand factor by ADAMTS13: a potential link of inflammation to TTP,” Blood, vol. 128, no. 1, pp. 110–119, 2016. View at Publisher · View at Google Scholar
  50. K. Martinod and D. D. Wagner, “Thrombosis: tangled up in NETs,” Blood, vol. 123, no. 18, pp. 2768–2776, 2014. View at Publisher · View at Google Scholar · View at Scopus
  51. T. A. Fuchs, A. Brill, D. Duerschmied et al., “Extracellular DNA traps promote thrombosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 36, pp. 15880–15885, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. J. Riegger, R. A. Byrne, M. Joner et al., “Histopathological evaluation of thrombus in patients presenting with stent thrombosis. A multicenter European study: a report of the prevention of late stent thrombosis by an interdisciplinary global European effort consortium,” European Heart Journal, vol. 37, no. 19, pp. 1538–1549, 2016. View at Publisher · View at Google Scholar · View at Scopus
  53. S. Grässle, V. Huck, K. I. Pappelbaum et al., “von Willebrand factor directly interacts with DNA from neutrophil extracellular traps,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 34, no. 7, pp. 1382–1389, 2014. View at Publisher · View at Google Scholar · View at Scopus
  54. R. Oklu, H. Albadawi, M. T. Watkins, M. Monestier, M. Sillesen, and S. Wicky, “Detection of extracellular genomic DNA scaffold in human thrombus: implications for the use of deoxyribonuclease enzymes in thrombolysis,” Journal of Vascular and Interventional Radiology, vol. 23, no. 5, pp. 712–718, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. A. A. Trillo and R. W. Prichard, “Early endothelial changes in experimental primate atherosclerosis,” Laboratory Investigation, vol. 41, no. 4, pp. 294–302, 1979. View at Google Scholar
  56. D. K. Vora, Z. T. Fang, S. M. Liva et al., “Induction of P-selectin by oxidized lipoproteins. Separate effects on synthesis and surface expression,” Circulation Research, vol. 80, no. 6, pp. 810–818, 1997. View at Google Scholar
  57. M. Galbusera, C. Zoja, R. Donadelli et al., “Fluid shear stress modulates von Willebrand factor release from human vascular endothelium,” Blood, vol. 90, no. 4, pp. 1558–1564, 1997. View at Google Scholar
  58. V. Fuster, E. J. W. Bowie, J. C. Lewis, D. N. Fass, C. A. Owen Jr., and A. L. Brown, “Resistance to arteriosclerosis in pigs with von Willebrand’s disease,” The Journal of Clinical Investigation, vol. 61, no. 3, pp. 722–730, 1978. View at Publisher · View at Google Scholar
  59. N. Methia, P. André, C. V. Denis, M. Economopoulos, and D. D. Wagner, “Localized reduction of atherosclerosis in von Willebrand factor-deficient mice,” Blood, vol. 98, no. 5, pp. 1424–1428, 2001. View at Google Scholar
  60. F. Qin, T. Impeduglia, P. Schaffer, and H. Dardik, “Overexpression of von Willebrand factor is an independent risk factor for pathogenesis of intimal hyperplasia: preliminary studies,” Journal of Vascular Surgery, vol. 37, no. 2, pp. 433–439, 2003. View at Publisher · View at Google Scholar · View at Scopus
  61. C. Gandhi, A. Ahmad, K. M. Wilson, and A. K. Chauhan, “ADAMTS13 modulates atherosclerotic plaque progression in mice via a VWF-dependent mechanism,” Journal of Thrombosis and Haemostasis, vol. 12, no. 2, pp. 255–260, 2014. View at Publisher · View at Google Scholar · View at Scopus
  62. S. Kageyama, H. Yamamoto, and R. Yoshimoto, “Anti-human von Willebrand factor monoclonal antibody AJvW-2 prevents thrombus deposition and neointima formation after balloon injury in guinea pigs,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 10, pp. 2303–2308, 2000. View at Google Scholar
  63. A. Yamashita, Y. Asada, H. Sugimura et al., “Contribution of von Willebrand factor to thrombus formation on neointima of rabbit stenotic iliac artery under high blood-flow velocity,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 6, pp. 1105–1110, 2003. View at Publisher · View at Google Scholar · View at Scopus
  64. D. Zahger, M. C. Fishbein, L. I. Garfinkel et al., “VCL, an antagonist of the platelet GP1b receptor, markedly inhibits platelet adhesion and intimal thickening after balloon injury in the rat,” Circulation, vol. 92, no. 5, pp. 1269–1273, 1995. View at Google Scholar
  65. H. Matsuno, O. Kozawa, M. Niwa, and T. Uematsu, “Inhibition of von Willebrand factor binding to platelet GP Ib by a fractionated aurintricarboxylic acid prevents restenosis after vascular injury in hamster carotid artery,” Circulation, vol. 96, no. 4, pp. 1299–1304, 1997. View at Google Scholar
  66. D. W. Chung, J. Chen, M. Ling et al., “High-density lipoprotein modulates thrombosis by preventing von Willebrand factor self-association and subsequent platelet adhesion,” Blood, vol. 127, no. 5, pp. 637–645, 2016. View at Publisher · View at Google Scholar · View at Scopus
  67. A. B. Federici, P. M. Mannucci, E. Fogato, P. Ghidoni, and L. Matturri, “Autopsy findings in three patients with von Willebrand disease type IIB and type III: presence of atherosclerotic lesions without occlusive arterial thrombi,” Thrombosis and Haemostasis, vol. 70, no. 5, pp. 758–761, 1993. View at Google Scholar
  68. B. Q. Zhao, A. K. Chauhan, M. Canault et al., “von Willebrand factor–cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke,” Blood, vol. 114, no. 15, pp. 3329–3334, 2009. View at Publisher · View at Google Scholar · View at Scopus
  69. C. Kleinschnitz, S. F. De Meyer, T. Schwarz et al., “Deficiency of von Willebrand factor protects mice from ischemic stroke,” Blood, vol. 113, no. 15, pp. 3600–3603, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. M. M. Khan, D. G. Motto, S. R. Lentz, and A. K. Chauhan, “ADAMTS13 reduces VWF-mediated acute inflammation following focal cerebral ischemia in mice,” Journal of Thrombosis and Haemostasis, vol. 10, no. 8, pp. 1665–1671, 2012. View at Publisher · View at Google Scholar · View at Scopus
  71. C. Gandhi, D. G. Motto, M. Jensen, S. R. Lentz, and A. K. Chauhan, “ADAMTS13 deficiency exacerbates VWF-dependent acute myocardial ischemia/reperfusion injury in mice,” Blood, vol. 120, no. 26, pp. 5224–5230, 2012. View at Publisher · View at Google Scholar · View at Scopus
  72. S. F. De Meyer, A. S. Savchenko, M. S. Haas et al., “Protective anti-inflammatory effect of ADAMTS13 on myocardial ischemia/reperfusion injury in mice,” Blood, vol. 120, no. 26, pp. 5217–5223, 2012. View at Publisher · View at Google Scholar · View at Scopus
  73. A. Elvington, C. Atkinson, H. Zhu et al., “The alternative complement pathway propagates inflammation and injury in murine ischemic stroke,” Journal of Immunology, vol. 189, no. 9, pp. 4640–4647, 2012. View at Publisher · View at Google Scholar · View at Scopus
  74. J. Mocco, W. J. Mack, A. F. Ducruet et al., “Complement component C3 mediates inflammatory injury following focal cerebral ischemia,” Circulation Research, vol. 99, no. 2, pp. 209–217, 2006. View at Publisher · View at Google Scholar · View at Scopus
  75. F. Gragnano, E. Golia, F. Natale et al., “The role of von Willebrand factor in cardiovascular disease: from a biochemical marker to an attractive therapeutic target,” Current Vascular Pharmacology, vol. 15, pp. 1–12, 2017. View at Publisher · View at Google Scholar
  76. E. Rurali, M. Noris, A. Chianca, BENEDICT Study Group et al., “ADAMTS13 predicts renal and cardiovascular events in type 2 diabetic patients and response to therapy,” Diabetes, vol. 62, no. 10, pp. 3599–3609, 2013. View at Publisher · View at Google Scholar · View at Scopus
  77. R. G. Wieberdink, M. C. van Schie, P. J. Koudstaal et al., “High von Willebrand factor levels increase the risk of stroke: the Rotterdam study,” Stroke, vol. 41, no. 10, pp. 2151–2156, 2010. View at Publisher · View at Google Scholar · View at Scopus
  78. Y. V. Sanders, J. Eikenboom, E. M. de Wee et al., “Reduced prevalence of arterial thrombosis in von Willebrand disease,” Journal of Thrombosis and Haemostasis, vol. 11, no. 5, pp. 845–854, 2013. View at Publisher · View at Google Scholar · View at Scopus
  79. P. Kraft, C. Drechsler, I. Gunreben et al., “Von Willebrand factor regulation in patients with acute and chronic cerebrovascular disease: a pilot, case-control study,” PloS One, vol. 9, no. 6 article e99851, 2014. View at Publisher · View at Google Scholar · View at Scopus
  80. S. G. Thompson, J. Kienast, S. D. Pyke, F. Haverkate, and J. C. van de Loo, “Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group,” The New England Journal of Medicine, vol. 332, no. 10, pp. 635–641, 1995. View at Publisher · View at Google Scholar · View at Scopus
  81. M. A. Sonneveld, J. M. Cheng, R. M. Oemrawsingh et al., “Von Willebrand factor in relation to coronary plaque characteristics and cardiovascular outcome. Results of the ATHEROREMO-IVUS study,” Thrombosis and Haemostasis, vol. 113, no. 3, pp. 577–584, 2015. View at Publisher · View at Google Scholar · View at Scopus
  82. B. Rutten, A. Maseri, D. Cianflone et al., “Plasma levels of active von Willebrand factor are increased in patients with first ST-segment elevation myocardial infarction: a multicenter and multiethnic study,” European Heart Journal. Acute Cardiovascular Care, vol. 4, no. 1, pp. 64–74, 2015. View at Publisher · View at Google Scholar · View at Scopus
  83. R. Marcucci, F. Cesari, S. Cinotti et al., “ADAMTS-13 activity in the presence of elevated von Willebrand factor levels as a novel mechanism of residual platelet reactivity in high risk coronary patients on antiplatelet treatment,” Thrombosis Research, vol. 123, no. 1, pp. 130–136, 2008. View at Publisher · View at Google Scholar · View at Scopus
  84. S. R. Cataland and H. M. Wu, “Acquired thrombotic thrombocytopenic purpura: new therapeutic options and their optimal use,” Journal of Thrombosis and Haemostasis, vol. 13, Supplement 1, pp. S223–S229, 2015. View at Publisher · View at Google Scholar · View at Scopus
  85. T. Ono, J. Mimuro, S. Madoiwa et al., “Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure,” Blood, vol. 107, no. 2, pp. 528–534, 2006. View at Publisher · View at Google Scholar · View at Scopus
  86. K. Martin, D. Borgel, N. Lerolle et al., “Decreased ADAMTS-13 (a disintegrin-like and metalloprotease with thrombospondin type 1 repeats) is associated with a poor prognosis in sepsis-induced organ failure,” Critical Care Medicine, vol. 35, no. 10, pp. 2375–2382, 2007. View at Google Scholar
  87. V. Peigne, E. Azoulay, I. Coquet et al., “The prognostic value of ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13) deficiency in septic shock patients involves interleukin-6 and is not dependent on disseminated intravascular coagulation,” Critical Care, vol. 17, no. 6, p. R273, 2013. View at Publisher · View at Google Scholar · View at Scopus
  88. A. Hyseni, H. Kemperman, D. W. de Lange, J. Kesecioglu, P. G. de Groot, and M. Roest, “Active von Willebrand factor predicts 28-day mortality in patients with systemic inflammatory response syndrome,” Blood, vol. 123, no. 14, pp. 2153–2156, 2014. View at Publisher · View at Google Scholar · View at Scopus
  89. J. Aibar, P. Castro, G. Espinosa et al., “ADAMTS-13 in critically ill patients with septic syndromes and noninfectious systemic inflammatory response syndrome,” Shock, vol. 43, no. 6, pp. 556–562, 2015. View at Publisher · View at Google Scholar · View at Scopus
  90. C. Hillgruber, A. K. Steingräber, B. Pöppelmann et al., “Blocking von Willebrand factor for treatment of cutaneous inflammation,” The Journal of Investigative Dermatology, vol. 134, no. 1, pp. 77–86, 2014. View at Publisher · View at Google Scholar · View at Scopus
  91. J. Huang, R. Roth, J. E. Heuser, and J. E. Sadler, “Integrin alpha(v)beta(3) on human endothelial cells binds von Willebrand factor strings under fluid shear stress,” Blood, vol. 113, no. 7, pp. 1589–1597, 2009. View at Publisher · View at Google Scholar · View at Scopus
  92. M. D. de Kruif, L. C. Lemaire, I. A. Giebelen et al., “Prednisolone dose-dependently influences inflammation and coagulation during human endotoxemia,” Journal of Immunology, vol. 178, no. 3, pp. 1845–1851, 2007. View at Google Scholar
  93. R. A. DeLa Cadena, A. Majluf-Cruz, A. Stadnicki et al., “Recombinant tumor necrosis factor receptor p75 fusion protein (TNFR:Fc) alters endotoxin-induced activation of the kinin, fibrinolytic, and coagulation systems in normal humans,” Thrombosis and Haemostasis, vol. 80, no. 1, pp. 114–118, 1998. View at Google Scholar
  94. A. Sahebkar, C. Serban, S. Ursoniu et al., “The impact of statin therapy on plasma levels of von Willebrand factor antigen. Systematic review and meta-analysis of randomised placebo-controlled trials,” Thrombosis and Haemostasis, vol. 115, no. 3, pp. 520–532, 2016. View at Publisher · View at Google Scholar · View at Scopus
  95. G. Montalescot, J. P. Collet, L. Lison et al., “Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina,” Journal of the American College of Cardiology, vol. 36, no. 1, pp. 110–114, 2000. View at Google Scholar
  96. S. Mousavi, M. Moradi, T. Khorshidahmad, and M. Motamedi, “Anti-inflammatory effects of heparin and its derivatives: a systematic review,” Advances in Pharmacological Sciences, vol. 2015, p. 507151, 2015. View at Publisher · View at Google Scholar · View at Scopus
  97. G. Montalescot, C. Bal-dit-Sollier, D. Chibedi et al., “Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study),” The American Journal of Cardiology, vol. 91, no. 8, pp. 925–930, 2003. View at Publisher · View at Google Scholar · View at Scopus
  98. I. Elbini Dhouib, M. Jallouli, A. Annabi, N. Gharbi, S. Elfazaa, and M. M. Lasram, “A minireview on N-acetylcysteine: an old drug with new approaches,” Life Sciences, vol. 151, pp. 359–363, 2016. View at Publisher · View at Google Scholar · View at Scopus
  99. J. Chen, A. Reheman, F. C. Gushiken et al., “N-Acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice,” The Journal of Clinical Investigation, vol. 121, no. 2, pp. 593–603, 2011. View at Publisher · View at Google Scholar · View at Scopus
  100. F. A. Sayani and C. S. Abrams, “How I treat refractory thrombotic thrombocytopenic purpura,” Blood, vol. 125, no. 25, pp. 3860–3867, 2015. View at Publisher · View at Google Scholar · View at Scopus
  101. F. Denorme and S. F. De Meyer, “The VWF-GPIb axis in ischaemic stroke: lessons from animal models,” Thrombosis and Haemostasis, vol. 116, no. 4, pp. 597–604, 2016. View at Publisher · View at Google Scholar · View at Scopus
  102. P. A. Lapchak, S. Doyan, X. Fan, and C. M. Woods, “Synergistic effect of AJW200, a von Willebrand factor neutralizing antibody with low dose (0.9 mg/mg) thrombolytic therapy following embolic stroke in rabbits,” Journal of Neurology & Neurophysiology, vol. 4, no. 2, p. 146, 2013. View at Publisher · View at Google Scholar
  103. A. Fontayne, M. Meiring, S. Lamprecht et al., “The humanized anti-glycoprotein Ib monoclonal antibody h6B4-Fab is a potent and safe antithrombotic in a high shear arterial thrombosis model in baboons,” Thrombosis and Haemostasis, vol. 100, no. 4, pp. 670–677, 2008. View at Google Scholar
  104. M. Wadanoli, D. Sako, G. D. Shaw et al., “The von Willebrand factor antagonist (GPG-290) prevents coronary thrombosis without prolongation of bleeding time,” Thrombosis and Haemostasis, vol. 98, no. 2, pp. 397–405, 2007. View at Google Scholar
  105. S. Kageyama, H. Yamamoto, H. Nakazawa et al., “Pharmacokinetics and pharmacodynamics of AJW200, a humanized monoclonal antibody to von Willebrand factor, in monkeys,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 1, pp. 187–192, 2002. View at Publisher · View at Google Scholar · View at Scopus
  106. H. Yamamoto, I. Vreys, J. M. Stassen, R. Yoshimoto, J. Vermylen, and M. F. Hoylaerts, “Antagonism of vWF inhibits both injury induced arterial and venous thrombosis in the hamster,” Journal of Thrombosis and Haemostasis, vol. 79, no. 1, pp. 202–210, 1998. View at Google Scholar
  107. S. Staelens, M. A. Hadders, S. Vauterin et al., “Paratope determination of the antithrombotic antibody 82D6A3 based on the crystal structure of its complex with the von Willebrand factor A3-domain,” The Journal of Biological Chemistry, vol. 281, no. 4, pp. 2225–2231, 2006. View at Publisher · View at Google Scholar · View at Scopus
  108. S. F. De Meyer, S. Staelens, P. N. Badenhorst et al., “Coronary artery in-stent stenosis persists despite inhibition of the von Willebrand factor—collagen interaction in baboons,” Thrombosis and Haemostasis, vol. 98, no. 6, pp. 1343–1349, 2007. View at Google Scholar
  109. Y. M. Zhao, M. Jiang, S. D. Ji et al., “Anti-human VWF monoclonal antibody SZ-123 prevents arterial thrombus formation by inhibiting VWF-collagen and VWF-platelet interactions in Rhesus monkeys,” Biochemical Pharmacology, vol. 85, no. 7, pp. 945–953, 2013. View at Publisher · View at Google Scholar · View at Scopus
  110. X. Ni, M. Castanares, A. Mukherjee, and S. E. Lupold, “Nucleic acid aptamers: clinical applications and promising new horizons,” Current Medicinal Chemistry, vol. 18, no. 27, pp. 4206–4214, 2011. View at Publisher · View at Google Scholar · View at Scopus
  111. A. O. Spiel, F. B. Mayr, N. Ladani et al., “The aptamer ARC1779 is a potent and specific inhibitor of von Willebrand factor mediated ex vivo platelet function in acute myocardial infarction,” Platelets, vol. 20, no. 5, pp. 334–340, 2009. View at Publisher · View at Google Scholar · View at Scopus
  112. H. S. Markus, C. McCollum, C. Imray, M. A. Goulder, J. Gilbert, and A. King, “The von Willebrand inhibitor ARC1779 reduces cerebral embolization after carotid endarterectomy: a randomized trial,” Stroke, vol. 42, no. 8, pp. 2149–2153, 2011. View at Publisher · View at Google Scholar · View at Scopus
  113. P. Knöbl, B. Jilma, J. C. Gilbert, R. M. Hutabarat, P. G. Wagner, and P. Jilma-Stohlawetz, “Anti-von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura,” Transfusion, vol. 49, no. 10, pp. 2181–2185, 2009. View at Publisher · View at Google Scholar · View at Scopus
  114. J. M. Siller-Matula, Y. Merhi, J. F. Tanguay et al., “ARC15105 is a potent antagonist of von Willebrand factor mediated platelet activation and adhesion,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 32, no. 4, pp. 902–909, 2012. View at Publisher · View at Google Scholar · View at Scopus
  115. J. A. Diaz, S. K. Wrobleski, C. M. Alvarado et al., “P-selectin inhibition therapeutically promotes thrombus resolution and prevents vein wall fibrosis better than enoxaparin and an inhibitor to von Willebrand factor,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 35, no. 4, pp. 829–837, 2015. View at Publisher · View at Google Scholar · View at Scopus
  116. O. Y. Dmitriev, S. Lutsenko, and S. Muyldermans, “Nanobodies as probes for protein dynamics in vitro and in cells,” The Journal of Biological Chemistry, vol. 291, no. 8, pp. 3767–3775, 2016. View at Publisher · View at Google Scholar
  117. F. Peyvandi, M. Scully, J. A. Kremer Hovinga et al., “Caplacizumab for acquired thrombotic thrombocytopenic purpura,” The New England Journal of Medicine, vol. 374, no. 6, pp. 511–522, 2016. View at Publisher · View at Google Scholar · View at Scopus
  118. A. K. Chauhan, D. G. Motto, C. B. Lamb et al., “Systemic antithrombotic effects of ADAMTS13,” The Journal of Experimental Medicine, vol. 203, no. 3, pp. 767–776, 2006. View at Publisher · View at Google Scholar · View at Scopus
  119. T. Nakano, K. Irie, K. Hayakawa et al., “Delayed treatment with ADAMTS13 ameliorates cerebral ischemic injury without hemorrhagic complication,” Brain Research, vol. 1624, pp. 330–335, 2015. View at Publisher · View at Google Scholar · View at Scopus
  120. L. Wang, W. Fan, P. Cai et al., “Recombinant ADAMTS13 reduces tissue plasminogen activator-induced hemorrhage after stroke in mice,” Annals of Neurology, vol. 73, no. 2, pp. 189–198, 2013. View at Publisher · View at Google Scholar · View at Scopus
  121. P. Cai, H. Luo, H. Xu et al., “Recombinant ADAMTS 13 attenuates brain injury after intracerebral hemorrhage,” Stroke, vol. 46, no. 9, pp. 2647–2653, 2015. View at Publisher · View at Google Scholar · View at Scopus
  122. C. Muroi, M. Fujioka, K. Mishima et al., “Effect of ADAMTS-13 on cerebrovascular microthrombosis and neuronal injury after experimental subarachnoid hemorrhage,” Journal of Thrombosis and Haemostasis, vol. 12, no. 4, pp. 505–514, 2014. View at Publisher · View at Google Scholar · View at Scopus
  123. A. Kopić, K. Benamara, C. Piskernik et al., “Preclinical assessment of a new recombinant ADAMTS-13 drug product (BAX930) for the treatment of thrombotic thrombocytopenic purpura,” Journal of Thrombosis and Haemostasis, vol. 14, no. 7, pp. 1410–1419, 2016. View at Publisher · View at Google Scholar · View at Scopus